Terms: = Breast cancer AND Cytokeratin�fragment 21-1 AND Treatment
237 results:
1. Metabolic syndrome and cardiovascular disease in cancer survivors.
Ueno K; Kaneko H; Suzuki Y; Okada A; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Kamiya K; Ako J; Node K; Yasunaga H; Komuro I
J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1062-1071. PubMed ID: 38515400
[TBL] [Abstract] [Full Text] [Related]
2. Long-term results of intraoperative multicatheter breast implant (IOMBI) for accelerated partial breast irradiation (APBI) on early breast cancer patients.
Gimeno-Morales M; Martínez-Monge R; Martinez-Lage A; Jablonska PA; Blanco J; Martínez-Regueira F; Rodriguez-Spiteri N; Olartecoechea B; Ramos L; Insausti LP; Elizalde A; Abengozar M; Cambeiro M
Radiother Oncol; 2024 May; 194():110193. PubMed ID: 38432310
[TBL] [Abstract] [Full Text] [Related]
3. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Cristea MC; Stewart D; Synold T; Ruel N; Mortimer J; Wang E; Jung A; Wilczynski S; Konecny GE; Eng M; Kilpatrick L; Han E; Dellinger T; Hakim A; Lee S; Morgan RJ; Wakabayashi MT; Frankel PH
Gynecol Oncol; 2024 Mar; 182():124-131. PubMed ID: 38262235
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of traditional Chinese medicine in the treatment of menopause-like syndrome for breast cancer survivors: a systematic review and meta-analysis.
Wang R; Wang Y; Fang L; Xie Y; Yang S; Liu S; Fang Y; Zhang Y
BMC Cancer; 2024 Jan; 24(1):42. PubMed ID: 38191442
[TBL] [Abstract] [Full Text] [Related]
5. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract] [Full Text] [Related]
6. 2020 Annual Report of National Clinical Database-breast cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
Sagara Y; Kumamaru H; Niikura N; Miyashita M; Konishi T; Iwamoto T; Sanuki N; Tanakura K; Nagahashi M; Hayashi N; Yoshida M; Kinukawa N; Watanabe C; Toi M; Saji S
Breast Cancer; 2024 Mar; 31(2):179-184. PubMed ID: 38180641
[TBL] [Abstract] [Full Text] [Related]
7. Mode of Detection of Second breast cancers in Patients Undergoing Surveillance After treatment of Ductal Carcinoma in Situ.
Waites BT; Lyon L; Kuehner G; Odele P; Habel LA; Liu R
J Natl Compr Canc Netw; 2023 Dec; 22(1):. PubMed ID: 38154251
[TBL] [Abstract] [Full Text] [Related]
8. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
Cuzick J; Chu K; Keevil B; Brentnall AR; Howell A; Zdenkowski N; Bonanni B; Loibl S; Holli K; Evans DG; Cummings S; Dowsett M
Lancet Oncol; 2024 Jan; 25(1):108-116. PubMed ID: 38070530
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
[TBL] [Abstract] [Full Text] [Related]
10. Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy.
Harbeck N; Kates R; Schinköthe T; Schumacher J; Wuerstlein R; Degenhardt T; Lüftner D; Räth P; Hoffmann O; Lorenz R; Decker T; Reinisch M; Göhler T; Staib P; Gluz O; Fasching PA; Schmidt M;
Cancer Treat Rev; 2023 Dec; 121():102631. PubMed ID: 37862832
[TBL] [Abstract] [Full Text] [Related]
11. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
Gumusay O; Huppert LA; Magbanua MJM; Wabl CA; Assefa M; Chien AJ; Melisko ME; Majure MC; Moasser M; Park J; Rugo HS
Breast Cancer Res Treat; 2024 Jan; 203(2):197-204. PubMed ID: 37815684
[TBL] [Abstract] [Full Text] [Related]
12. The utility of H2 receptor antagonists in preventing infusion-related reactions to paclitaxel chemotherapy.
Tsang C; Robinson J; Wheatley-Price PF; Brule SY; Moore SM
Cancer; 2023 Dec; 129(23):3815-3819. PubMed ID: 37665180
[TBL] [Abstract] [Full Text] [Related]
13. Advance Directives for Patients With breast cancer: Applying the Right Info/Right Care/Right Patient/Right Time Oncology Model.
Ossowski S; Lyon L; Linehan E; Gordon NP; Egorova O; Mark B; Beringer K; Abbe T; Shirazi A; Weldon C; Trosman J; Ravelo A; Liu R
Perm J; 2023 Sep; 27(3):30-36. PubMed ID: 37255340
[TBL] [Abstract] [Full Text] [Related]
14. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Bliss JM; Tovey H; Evans A; Holcombe C; Horgan K; Mallon E; Vidya R; Skene A; Dodson A; Hills M; Detre S; Zabaglo L; Banerji J; Kilburn L; Morden JP; Robertson JFR; Smith I; Dowsett M;
Breast Cancer Res; 2023 Apr; 25(1):39. PubMed ID: 37046348
[TBL] [Abstract] [Full Text] [Related]
15. Assessment of a Peer Physician Coaching Partnership Between a Designated cancer Center Genetics Service and a Community cancer Network Hospital.
Santos LG; Buzdnitskaya T; Rolf BA; Souza W; Sienko M; Ruiz-Bonilla JA; Shah B; Jewell P; Jensen L; Horike-Pyne M; Elrod JA; Crews J; Laurino M; Weeks KA; Dubard-Gault ME
JAMA Netw Open; 2023 Mar; 6(3):e231723. PubMed ID: 36877518
[TBL] [Abstract] [Full Text] [Related]
16. Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
Liede A; Sebby W; Miriyala AKR; Potluri R; Mazumder D; Ghosh A; Papademetriou E; Kilpatrick R; Tyczynski JE
BMC Cancer; 2023 Jan; 23(1):78. PubMed ID: 36690978
[TBL] [Abstract] [Full Text] [Related]
17. Early nutritional intervention does not prevent long-term adverse events in women with breast cancer: A pilot study.
Denise de Lima Bezerra A; Matias de Sousa I; Silva de Souza AP; Miranda de Carvalho AL; Trussardi Fayh AP
Clin Nutr ESPEN; 2023 Feb; 53():268-273. PubMed ID: 36657923
[TBL] [Abstract] [Full Text] [Related]
18. Trajectories of quality of life in breast cancer survivors during the first year after treatment: a longitudinal study.
Park JH; Jung YS; Kim JY; Bae SH
BMC Womens Health; 2023 Jan; 23(1):12. PubMed ID: 36627606
[TBL] [Abstract] [Full Text] [Related]
19. Combination of Chinese medicinal formulas and chemotherapy for triple-negative breast cancer strengthens body resistance to eliminate pathogenic factors.
Zhang Y; Mo JW; Lu HZ; Han LL; Liu C; Zhou Y
Medicine (Baltimore); 2022 Dec; 101(51):e32350. PubMed ID: 36595868
[TBL] [Abstract] [Full Text] [Related]
20. Dermal-adipose lymphatic flap venous wrapping: A novel lymphaticovenous shunt method for progression of upper extremity lymphedema with severe lymphosclerosis.
Yamamoto T; Miyazaki T; Sakai H; Tsukuura R; Yamamoto N
J Vasc Surg Venous Lymphat Disord; 2023 May; 11(3):619-625.e2. PubMed ID: 36580998
[TBL] [Abstract] [Full Text] [Related]
[Next]
